Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lixivaptan
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Centessa Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lixivaptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Polycystic Kidney, Autosomal Dominant.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 26, 2022
Lead Product(s) : Lixivaptan
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Centessa Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lixivaptan
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Centessa Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Palladio Biosciences Doses First Patient With Lixivaptan in The ALERT Study
Details : The ALERT Study, designed to assess the safety of lixivaptan in autosomal dominant polycystic kidney disease (ADPKD) patients who previously discontinued therapy with tolvaptan due to liver toxicity, is currently recruiting patients in the United States.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 17, 2020
Lead Product(s) : Lixivaptan
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Centessa Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lixivaptan
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Centessa Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The presentation will include the results of more than 12 months of safe treatment with lixivaptan in this study, which was conducted as an expanded access clinical study under an IND.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 20, 2020
Lead Product(s) : Lixivaptan
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Centessa Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable